Otsuka Pharmaceutical Co. Ltd. is paying up to $1.3bn for private US-based drug discovery specialist Jnana Therapeutics Inc., in a deal that will give the Japanese major access to platform technology and phenylketonuria asset it sees as complementing its existing portfolio and earlier acquisitions.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?